Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
EN3342 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| EN3342 | EXPERIMENTAL | EN3342 (risperidone) subcutaneous implant |
| Name | Type | Description |
|---|---|---|
| EN3342 | DRUG | - |
Subject Inclusion Criteria 1. Subject (and/or a subject's authorized legal representative) has provided written informed consent 2. Subject has identified a caregiver or personal contact with whom the subject has significant contact with at least once per week 3. Subject is male or female of non-ch...
EN3342 is an investigational small molecule being developed for the treatment of schizophrenia. It is currently in Phase 1 clinical development and has not been approved by the FDA. The drug is being studied in stabilized schizophrenic patients to evaluate its pharmacokinetics.
EN3342 is being developed by BrainsWay Ltd., a company traded on the stock exchange under the ticker BWAY. The company is conducting clinical research on this investigational drug for schizophrenia, with the asset currently in Phase 1 development.
EN3342 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 study has been completed, and the drug remains under clinical investigation for schizophrenia.
EN3342 has one completed clinical trial, identified as NCT01774435. This Phase 1 study evaluated the pharmacokinetics of risperidone and 9-hydroxy-risperidone when risperidone is administered from a polyurethane implant in stabilized schizophrenic patients. The trial enrolled 35 participants in the United States.
EN3342 is associated with the administration of risperidone from a polyurethane implant. The completed clinical trial for EN3342 evaluated the pharmacokinetics of risperidone and its metabolite 9-hydroxy-risperidone when delivered via this implant in patients with schizophrenia.